As for the other MKIs and selective kinase inhibitors, especially selective kinase inhibitors that restore RAI uptake in tumor cells (such as BRAF, MEK and mTOR inhibitors), encouraging results are shown in multiple clinical trials. The gene discussed is BRAF; the disease is neoplasm.